治療的血漿交換市場- 世界の産業規模、シェア、動向、機会、予測、製品別、技術別、適応症別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

治療的血漿交換の世界市場は、2024年に16億4,000万米ドルと評価され、予測期間中のCAGRは7.77%で2030年には25億7,000万米ドルに達すると予測されています。

治療的血漿交換（TPE）は、プラズマフェレーシスとしても知られ、顧客の血液から病原性物質を分離し、アルブミン溶液や新鮮凍結血漿などの置換液と置き換えるために利用される血管内血液技術です。これらの物質には、感染性自己抗体、免疫複合体、クリオグロブリン、コレステロール含有リポ蛋白などが含まれます。TPEは様々な自己免疫疾患、腎疾患、血液疾患などの治療に使用され、市場拡大に貢献しています。その他の特典として、TPEには血漿粘度を低下させるという大きな利点があります。血漿交換は、第一選択療法または第二選択療法として、あるいは支持療法として、慢性疾患の管理において広く行われています。血漿交換では、毒素やその他の異常物質を含む血漿のかなりの部分が他の血液成分から抽出され、新鮮凍結血漿（FFP）やアルブミンなどの置換液と交換されます。

市場促進要因

神経疾患、腎疾患、血液疾患の高い有病率

主要市場の課題

プラズマフェレーシス手技に伴うリスク

主な市場動向

継続的な進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の治療的血漿交換市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（消耗品、デバイス）
  • 技術別（遠心分離、膜分離）
  • 適応症別（神経疾患、血液疾患、腎疾患、代謝疾患、その他）
  • エンドユーザー別（採血センター・血液成分供給業者、病院・診療所、輸血センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の治療的血漿交換市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の治療的血漿交換市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の治療的血漿交換市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の治療的血漿交換市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの治療的血漿交換市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界の治療的血漿交換市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Asahi Kasei Corporation
• Baxter International Inc
• B. Braun Melsungen AG
• Cerus Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Hemacare Corporation
• IncMedica S.p.A.
• Kawasumi Laboratories
• Terumo Corporation

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Therapeutic Plasma Exchange Market was valued at USD 1.64 Billion in 2024 and is expected to reach USD 2.57 Billion by 2030 with a CAGR of 7.77% during the forecast period. Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an endovascular blood technique utilized to separate pathogenic substances from clients' blood and replace them with replacement fluid, such as albumin solution or fresh frozen plasma. These substances encompass infective autoantibodies, immune complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is employed in the treatment of various autoimmune conditions, renal disorders, hematological disorders, and more, contributing to market expansion. Additionally, therapeutic plasma exchange (TPE) offers the significant benefit of reducing plasma viscosity. It is widely performed in the management of chronic diseases as a first-line or second-line therapy, or as a supportive treatment. During plasma exchange, a substantial portion of plasma containing toxins and other abnormal matter is extracted from the other blood components and replaced with replacement fluid, such as fresh frozen plasma (FFP) or albumin.

Key Market Drivers

High prevalence of Neurological, Renal, And Hematological Disorders

The high prevalence of chronic diseases, such as nephrological disorders, acute liver failure, Guillain-Barre Syndrome (GBS), and others, contributes to the growth of the overall therapeutic plasma exchange market. Additionally, there has been a surge in the application of therapeutic plasma exchange, accompanied by intensive research and clinical trials to assess its efficacy compared to other treatments. These factors significantly bolster the growth of the therapeutic plasma exchange market. The most common indications for TPE therapy are nephrology-related disorders, as well as its use in the treatment of myasthenia gravis, Guillain Barre syndrome (GBS), and chronic inflammatory demyelinating polyneuropathy. Currently, the trend in therapeutic plasma exchange involves the use of highly permeable filters and standard dialysis equipment, often referred to as membrane plasma separation (MPS). In the US, the "Plasmaflo" membrane from Asahi Medical (Asahi Kasei Kuraray Medical Co., Ltd, Japan) is widely used.

Key Market Challenges

Risk Associated with Plasmapheresis Procedures

During the plasmapheresis procedure, a portion of blood is extracted from the human body, and specific replacement fluids like albumin, fresh frozen plasma (FFP), electrolyte solutions, purified protein products, and starches are administered intravenously to maintain intravascular osmotic pressure. Although generally considered safe, there are still several associated risks. Risk factors include infection, allergic reactions, hypotension, internal bleeding, electrolyte imbalance, and others. One of the most frequent side effects of plasmapheresis is hypotension, characterized by symptoms such as faintness, blurred vision, dizziness, sweating, or abdominal cramps. However, prompt treatment can effectively manage these symptoms. Some patients may experience numbness or tingling around the mouth or nose due to the effect of the anticoagulant citrate on calcium levels in the body. In rare cases, bleeding may occur during the procedure as a result of anticoagulants added to the blood, potentially leading to irregular heartbeat and cardiac arrest if not promptly addressed. Allergic reactions, itching, and rash may also occur as a response to the replacement fluids, but these can be easily treated with intravenous medication. These side effects may impede the widespread adoption of plasmapheresis, thereby limiting market growth to some extent.

Key Market Trends

Continuous Advancement

Continuous technological advancements have significantly enhanced and refined high-precision methods. These advancements not only improve patient satisfaction but also enhance the processing of goods derived from blood and plasma. In comparison to other techniques such as membrane separation methods, this method requires minimal blood flow, making it a more advanced approach for facilitating blood collection through the patient's antecubital or radial veins. Moreover, these technological advancements allow for more precise control of hydration status, resulting in greater hemodynamic stability during treatment. Additionally, patients benefit from improved comfort and safety during therapeutic plasma exchange (TPE) procedures. These remarkable technological developments create lucrative opportunities within the market.

Key Market Players

• Asahi Kasei Corporation
• Baxter International Inc
• B. Braun Melsungen AG
• Cerus Corporation
• Fresenius Kabi AG
• Haemonetics Corporation
• Hemacare Corporation
• IncMedica S.p.A.
• Kawasumi Laboratories
• Terumo Corporation

Report Scope:

In this report, the Global Therapeutic Plasma Exchange Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Therapeutic Plasma Exchange Market, By Product:

• Consumables
• Devices

Therapeutic Plasma Exchange Market, By Technology:

• Centrifugation
• Membrane Separation

Therapeutic Plasma Exchange Market, By Indication:

• Neurological Disorders
• Haematology Disorders
• Renal Disorders
• Metabolic Disorders
• Others

Therapeutic Plasma Exchange Market, By End User:

• Blood Collection Centres & Blood Component Providers
• Hospitals & Clinics
• Blood Transfusion Centres
• Others

Therapeutic Plasma Exchange Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Therapeutic Plasma Exchange Market.

Available Customizations:

Global Therapeutic Plasma Exchange market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutic Plasma Exchange Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables, Devices)
  • 5.2.2. By Technology (Centrifugation, Membrane Separation)
  • 5.2.3. By Indication (Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, Others)
  • 5.2.4. By End User (Blood Collection Centers & Blood Component Providers, Hospitals & Clinics, Blood Transfusion Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Therapeutic Plasma Exchange Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Therapeutic Plasma Exchange Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Therapeutic Plasma Exchange Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Therapeutic Plasma Exchange Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By End User

7. Europe Therapeutic Plasma Exchange Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Therapeutic Plasma Exchange Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Therapeutic Plasma Exchange Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Therapeutic Plasma Exchange Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By End User
  • 7.3.4. France Therapeutic Plasma Exchange Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Therapeutic Plasma Exchange Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By End User

8. Asia-Pacific Therapeutic Plasma Exchange Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Therapeutic Plasma Exchange Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By End User
  • 8.3.2. India Therapeutic Plasma Exchange Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Therapeutic Plasma Exchange Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Therapeutic Plasma Exchange Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Therapeutic Plasma Exchange Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By End User

9. South America Therapeutic Plasma Exchange Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Therapeutic Plasma Exchange Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Therapeutic Plasma Exchange Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Therapeutic Plasma Exchange Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By End User

10. Middle East and Africa Therapeutic Plasma Exchange Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Indication
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Therapeutic Plasma Exchange Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Therapeutic Plasma Exchange Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Therapeutic Plasma Exchange Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Therapeutic Plasma Exchange Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Asahi Kasei Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Baxter International Inc
• 15.3. B. Braun Melsungen AG
• 15.4. Cerus Corporation
• 15.5. Fresenius Kabi AG
• 15.6. Haemonetics Corporation
• 15.7. Hemacare Corporation
• 15.8. IncMedica S.p.A.
• 15.9. Kawasumi Laboratories
• 15.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer